Dr. Sledge is on Doximity
As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
900 Blake Wilbur Dr
Palo Alto, CA 94304Phone(650) 498-6004
Fax(650) 498-5840- Is this information wrong?
Education & Training
University of Texas Health Science Center - San AntonioFellowship, Medical Oncology, 1981 - 1983
St Louis University School of MedicineResidency, Internal Medicine, 1977 - 1980
Tulane University School of MedicineClass of 1977
Certifications & Licensure
CA State Medical License 2013 - 2022
IN State Medical License 1983 - 2013
LA State Medical License 1977 - 1983- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- A Study of LY2835219 Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 01Panwalkar, A.,Tiersten, A.,WHITTENBERGER, B.,Stokoe, C.,Jones, C.,Patt, D.,Tamkus, D.,Khan, D.,Khan, F.,Holmes, F.,Wright, G.,Sledge, G.,Wang, G.,Koh, H.,Soliman, H.,Rugo, H.,Reynolds, J.,Vu, J.,Beck, J.,...
- Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer Start of enrollment: 2009 Aug 01Sledge, G.
- Lonafarnib in Metastatic Breast Cancer Start of enrollment: 2008 Oct 01Leland-Jones, B.,Sledge, G.
- Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer Start of enrollment: 2007 Sep 01Sledge, G.
- Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer Start of enrollment: 2006 Oct 01Sledge, G.W.
- Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance Start of enrollment: 2005 Oct 01Sledge, G.W.,Wagner, L.,Champion, V.
- Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01 Start of enrollment: 2005 Sep 01Miller, K.,Sledge, G.
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsNovel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer.Dhanir Tailor, Catherine C. Going, Angel Resendez, Vineet Kumar, Dhanya K. Nambiar, Yang Li, Arpit Dheeraj, Edward L. LaGory, Ali Ghoochani, Alisha M. Birk, Tanya Stoy...> ;British Journal of Cancer. 2021 Feb 2
- 5 citationsRace, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial.Kathy S. Albain, Robert Gray, Della F. Makower, Amir Faghih, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, S...> ;Journal of the National Cancer Institute. 2020 Sep 28
- 1 citationsSusan G. Komen Big Data for Breast Cancer Initiative: How Patient Advocacy Organizations Can Facilitate Using Big Data to Improve Patient OutcomesJerome Jourquin, Stephanie Birkey Reffey, Cheryl Jernigan, Mia A. Levy, Glendon Zinser, Kimberly Sabelko, Jennifer A. Pietenpol, George W. Sledge> ;JCO precision oncology. 2019 Sep 12
- Join now to see all
Press Mentions
Urges Commitment to Conquer Metastatic Breast CancersOctober 14th, 2019
Now with Survival Benefit, CDK4/6 Inhibitors in Breast CancerOctober 10th, 2019- Addition of CDK4/6 Inhibitors to Faslodex Improves Survival in Breast Cancer SubgroupSeptember 30th, 2019
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Stanford Health CarePalo Alto, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
